Director Drug Substance & Analytics Peptide API Leader

Zealand Pharma; Sabro; On-site; DKK 1,500,000 - 2,300,000; Full time

Job summary

Zealand Pharma A/S in Denmark seeks a Director, Head of Drug Substance & Analysis within Pharmaceutical Development to lead synthetic peptide DS development and analytical method development from early research through Phase 2, defining strategy and ensuring scalable processes.

You will own the DS portfolio, drive external CMO collaborations, build a high‑performing team, and partner with CMC stakeholders to advance programs while upholding GMP and regulatory standards.

Qualifications

• PhD in chemistry, biochemistry, pharmaceutical sciences, or similar.
• 10+ years of pharmaceutical industry experience within CMC (preferred).
• Strong expertise in synthetic peptide DS development and manufacturing.
• Knowledge of analytical method development for peptide APIs.
• GMP, regulatory submissions knowledge.
• Proven leadership including outsourcing to CMOs and external partnerships.

Responsibilities

• Lead and develop a high-performing team with clear direction and resource planning.
• Define and drive DS and analytical development strategies from early research through Phase 2.
• Drive DS process development with external CMOs, including oversight and key decisions.
• Collaborate with internal DS lab to strengthen process development and capabilities.
• Foster cross-functional collaboration across projects, CMOs, and partners.

Skills

Scientific leadership

CMC knowledge

Analytical method development

Regulatory submissions

Outsourcing to CMOs

Education

PhD in chemistry/biochemistry/pharmaceutical sciences

Job description

Zealand Pharma A/S in Denmark seeks a Director, Head of Drug Substance & Analysis within Pharmaceutical Development to lead synthetic peptide DS development and analytical method development from early research through Phase 2, defining strategy and ensuring scalable processes.

You will own the DS portfolio, drive external CMO collaborations, build a high‑performing team, and partner with CMC stakeholders to advance programs while upholding GMP and regulatory standards.